Guillaume Roquin
Centre Hospitalier Universitaire d'Angers(FR)Université d'Angers(FR)
Publications by Year
Research Areas
Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies, Neuroblastoma Research and Treatments, Pancreatic and Hepatic Oncology Research, Gastrointestinal Tumor Research and Treatment
Most-Cited Works
- → Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)(2020)164 cited
- → Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort(2017)109 cited
- → Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE)(2019)59 cited
- → Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements(2023)46 cited
- → Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial(2023)44 cited
- → Management of gastric neuro-endocrine tumours in a large French national cohort (GTE)(2017)28 cited
- → First Report of Lamotrigine-Induced Drug Rash with Eosinophilia and Systemic Symptoms Syndrome with Pancreatitis(2010)27 cited
- → Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors(2021)26 cited
- → Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)(2017)20 cited
- → Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study(2017)20 cited